<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03923478</url>
  </required_header>
  <id_info>
    <org_study_id>ABI-M201-101</org_study_id>
    <nct_id>NCT03923478</nct_id>
  </id_info>
  <brief_title>ABI-M201 in Adult Subjects With Mildly-to-Moderately Active Ulcerative Colitis</brief_title>
  <official_title>A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Phase 1b Study to Evaluate the Safety, Efficacy and Mircobiological Response of Oral ABI-M201 in Subjects With Mildly-to-Moderately Active UC With Ongoing Mesalamine Treatment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assembly Biosciences</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assembly Biosciences</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Phase 1B randomized, double-blind, placebo-controlled, two-cohort clinical trial of ABI-M201&#xD;
      in adult subjects with mildly-to-moderately active Ulcerative Colitis(UC) and ongoing&#xD;
      treatment with mesalamine.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This multi-center randomized, double-blind, placebo-controlled study will evaluate the safety&#xD;
      of ABI-M201 and its effects on disease activity measures in men and women with&#xD;
      mildly-to-moderately active UC and ongoing treatment with mesalamine. The study will consist&#xD;
      of 2 sequential, non-overlapping participant cohorts, separated by intervening interim&#xD;
      analysis (IA). Both cohorts will involve 8-weeks of study drug treatment. Interim data from&#xD;
      the initial treatment cohort (Cohort A) will inform decision to advance to the subsequent&#xD;
      second cohort (Cohort B) and its dose selection. 20 subjects will be randomized to cohort A&#xD;
      (1:1 allocation) and receive treatment with 1 capsule per day of ABI-M201 versus Placebo. 24&#xD;
      subjects will be randomized to cohort B (3:1 allocation) and receive treatment with up to 5&#xD;
      capsules one time a day of ABI-M201 versus Placebo.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Sponsor Decision&#xD;
  </why_stopped>
  <start_date type="Actual">June 24, 2019</start_date>
  <completion_date type="Actual">January 20, 2021</completion_date>
  <primary_completion_date type="Actual">January 20, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Double blind, placebo-controlled trial involving two sequential non-overlapping cohorts, with intervening interim analysis</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of Treatment-Emergent Adverse Events</measure>
    <time_frame>8-weeks</time_frame>
    <description>[Safety]</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of Treatment-Emergent Laboratory Abnormalities</measure>
    <time_frame>8-weeks</time_frame>
    <description>[Safety]</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical Remission</measure>
    <time_frame>8-weeks</time_frame>
    <description>[UC Disease Activity]</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Endoscopic Improvement</measure>
    <time_frame>8-weeks</time_frame>
    <description>[UC Disease Activity]</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">15</enrollment>
  <condition>Ulcerative Colitis Chronic Mild</condition>
  <condition>Ulcerative Colitis Chronic Moderate</condition>
  <arm_group>
    <arm_group_label>ABI-M201</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cohort A: 1 capsule one time a day&#xD;
Cohort B: 1- 5 capsules one time a day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Cohort A: 1 capsule one time a day&#xD;
Cohort B: 1-5 capsules one time a day</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ABI-M201</intervention_name>
    <description>Active Treatment</description>
    <arm_group_label>ABI-M201</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Control Treatment</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Established diagnosis of UC for at least 3 months prior to screening, with minimum&#xD;
             disease extent of 15 cm from the anal verge&#xD;
&#xD;
          -  Mildly to moderately active UC&#xD;
&#xD;
          -  Inadequate response to ongoing treatment with oral mesalamine ≥2.4 g/day for ≥4 weeks&#xD;
             from screening visit&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Possible or confirmed diagnosis of Crohn's Disease or other forms of inflammatory&#xD;
             bowel disorders&#xD;
&#xD;
          -  Ongoing or failed prior treatment for UC with methotrexate, azathioprine,&#xD;
             6-mercaptopurine, cyclosporine, tofacitinib, mycophenolate mofetil, sirolimus&#xD;
             (rapamycin), thalidomide, tacrolimus (FK-506), or biologics (e.g.,&#xD;
             TNF-alpha-antagonists, anti-integrin therapies, or agents targeting IL-12 or IL-23,&#xD;
             etc.)&#xD;
&#xD;
          -  Any immunosuppressive condition or treatment with immunosuppressive medications&#xD;
&#xD;
          -  History of prior surgical intervention in any region of the gastrointestinal tract&#xD;
             (excluding minor surgery)&#xD;
&#xD;
          -  Prior diagnosis of any cardiovascular, renal, hepatic, endocrine, infectious,&#xD;
             hematological, oncologic, neuro-psychiatric or immune-mediated disorder, which in the&#xD;
             opinion of the Principal Investigator might impact the subject's safety or compliance,&#xD;
             or the interpretation of results&#xD;
&#xD;
          -  Treatment with any other investigational drugs ≤12 weeks prior to baseline visit&#xD;
&#xD;
          -  The participant has a condition or is in a situation which, in the Principal&#xD;
             Investigator's opinion, may put the participant at significant risk, may confound the&#xD;
             study results, or may interfere significantly with the participant's participation in&#xD;
             the study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>(Investigator site)</name>
      <address>
        <city>Oakland</city>
        <state>California</state>
        <zip>94612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>(Investigator Site)</name>
      <address>
        <city>San Carlos</city>
        <state>California</state>
        <zip>94070</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>(Investigator Site)</name>
      <address>
        <city>Decatur</city>
        <state>Georgia</state>
        <zip>30033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>(Investigator Site)</name>
      <address>
        <city>Shreveport</city>
        <state>Louisiana</state>
        <zip>71105</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>(Investigator Site)</name>
      <address>
        <city>Chesterfield</city>
        <state>Michigan</state>
        <zip>48047</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>(Investigator Site)</name>
      <address>
        <city>Ypsilanti</city>
        <state>Michigan</state>
        <zip>48197</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>(Investigator Site)</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>(Investigator Site)</name>
      <address>
        <city>Jackson</city>
        <state>Tennessee</state>
        <zip>38305</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>(Investigator Site)</name>
      <address>
        <city>Bellevue</city>
        <state>Washington</state>
        <zip>98004</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>(Investigator Site)</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53226</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>(Investigator site)</name>
      <address>
        <city>Sudbury</city>
        <state>Ontario</state>
        <zip>P3C 5K6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>April 15, 2019</study_first_submitted>
  <study_first_submitted_qc>April 17, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">April 22, 2019</study_first_posted>
  <last_update_submitted>March 17, 2021</last_update_submitted>
  <last_update_submitted_qc>March 17, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Phase 1B</keyword>
  <keyword>Randomized</keyword>
  <keyword>Placebo Controlled</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colitis</mesh_term>
    <mesh_term>Colitis, Ulcerative</mesh_term>
    <mesh_term>Ulcer</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

